Efficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsis

Basit Öğe Kaydı
dc.authorscopusid23060531400
dc.authorscopusid6505508467
dc.authorscopusid57211248494
dc.authorscopusid6602534012
dc.authorscopusid7004827493
dc.authorscopusid23494580100
dc.authorscopusid8726721500
dc.contributor.authorKarabay O.
dc.contributor.authorBatirel A.
dc.contributor.authorBalkan I.I.
dc.contributor.authorAgalar C.
dc.contributor.authorAkalin S.
dc.contributor.authorAlici O.
dc.contributor.authorAlp E.
dc.date.accessioned2024-06-12T10:28:08Z
dc.date.available2024-06-12T10:28:08Z
dc.date.issued2014
dc.description.abstractObjective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (45.2%) cases were male and the mean age was 60.2 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38°C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (54.2%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33.3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality.en_US
dc.identifier.endpage1143en_US
dc.identifier.issn0393-6384
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-84907520572en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1137en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17097
dc.identifier.volume30en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcinetobacter Baumannii; Bacteremia; Colistin; Monotherapy; Multi-Drug Resistant; Sepsisen_US
dc.subjectCefoperazone Plus Sulbactam; Colistin; Creatinine; Imipenem; Meropenem; Piperacillin Plus Tazobactam; Tigecycline; Acinetobacter Baumannii; Acinetobacter Infection; Adult; Antibiotic Resistance; Apache; Article; Ataxia; Blood Culture; Charlson Comorbidity Index; Controlled Study; Creatinine Blood Level; Disease Severity; Drug Efficacy; Drug Safety; Female; Follow Up; Gram Negative Sepsis; Human; Intensive Care Unit; Loading Drug Dose; Major Clinical Study; Male; Mental Disease; Minimum Inhibitory Concentration; Monotherapy; Multi Drug Resistant Acinetobacter Baumannii Bacteremia; Multi Drug Resistant Acinetobacter Baumannii Bacteremia; Multicenter Study (Topic); Multidrug Resistance; Nephrotoxicity; Neurologic Disease; Pathogen Clearance; Retrospective Study; Risk Factor; Seizure; Tertiary Care Center; Treatment Duration; Treatment Outcome; Vertigo; Visual Disorderen_US
dc.titleEfficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu